EU Clinical Studies Lack Proper Design, Informed Consent – FDA Survey
This article was originally published in The Gray Sheet
Executive Summary
European data used to support 510(k) and PMA submissions to FDA often are marred by major flaws in protocol noncompliance and study management, according to agency-observed trends